<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Immunomic Therapeutics, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=35062></link><description><![CDATA[Immunomic Therapeutics, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Tue, 21 Apr 2026 09:24:48 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2020/05/12_3554238800_20200506195642_9608503393.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[이뮤노믹 테라퓨틱스, 신규 이사회 이사 임명 발표]]></title><link>https://www.newswire.co.kr/newsRead.php?no=904581</link><description><![CDATA[록빌, 메릴랜드--(Business Wire/뉴스와이어)--핵산 면역치료 플랫폼 연구를 개척하는 비상장 임상단계 생명공학 기업인 이뮤노믹 테라퓨틱스(Immunomic Therapeutics, Inc.)(이하 ‘ITI’)가 에이치엘비(HLB, Co. Ltd)(HLB) 및 에이치엘비 바이오(HLB Bio) 자회사의 경영진 5명을 자사 이사회 이사로 새로 임명했다고 5일 발표했다.    윌리엄 헐(William Hearl) 이뮤노믹 테라퓨틱스 최고경영자(CEO)는 “특출한 과학적 전...]]></description><pubDate>Wed, 06 May 2020 20:05:32 +0900</pubDate></item><item><title><![CDATA[Immunomic Therapeutics Announces Appointments to its Board of Directors]]></title><link>https://www.newswire.co.kr/newsRead.php?no=904580</link><description><![CDATA[ROCKVILLE, Md.--(Business Wire/Korea Newswire)--Immunomic Therapeutics, Inc., (“ITI”) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the appointment of five new members to its Board of Directors from HLB, Co. Ltd (“HLB”) and its HLB Bio subsidiaries.  “I am delighted to welcome the new members from HLB to our...]]></description><pubDate>Wed, 06 May 2020 19:59:06 +0900</pubDate></item></channel></rss>